We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health
News

Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health

Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health
News

Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Corgenix Signs Cooperative Research and Development Agreement with National Institutes of Health"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Corgenix Medical Corporation has announced it has entered into a corporative research and development agreement (CRADA) with the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

The two-year study will use the Corgenix Hyaluronic Acid (HA) test kit alone and in combination with other liver fibrosis biomarkers, to develop a predictive model for liver fibrosis in non-alcoholic steatohepatitis (NASH) patients.

NASH patients are typically diagnosed using invasive liver biopsy procedures. The Corgenix-NIDDK study is focused on developing a noninvasive method of diagnosis.

The aim of this study is to identify non-invasive, reliable markers to identify patients at risk for NASH.

“We are very excited about our collaboration with the NIH. This is a definitive study that will apply our HA product to a very important and clearly under-diagnosed condition that affects a significant percentage of the U.S. population,” said Corgenix President and Chief Executive Officer Douglass Simpson.

“With the rate of obesity in the U.S. continuing to increase, the prevalence of NASH will increase as well, and it will be even more important to have effective, non-invasive methods for assessment,” Simpson added.

“Nonalcoholic steatohepatitis is a major healthcare problem. It is typically a ‘silent’ disease with few or no symptoms until the disease is advanced,” said Luis Lopez, M.D., Corgenix Chief Medical Officer.

“NASH patients whose disease has progressed to cirrhosis have a 7-10 year mortality of up to 25 percent. We believe this study has the potential to make a major difference in literally millions of individuals when completed,” said Lopez.

Advertisement